Circulating miR-10b-5p drives Kawasaki vasculitis through endothelial reprogramming and nominates CXCL8 as an early diagnostic biomarker

This study identifies circulating miR-10b-5p as a key driver of Kawasaki disease vasculitis that reprograms endothelial cells via the MKI67/CBX5-CEBPA axis to upregulate CXCL8, thereby establishing serum CXCL8 as a promising early diagnostic biomarker for the disease.

The Gist

The Hidden Alarm System: How a Tiny Molecule Triggers Kawasaki Disease

Imagine your body's blood vessels as a busy highway system. Normally, the "road workers" (endothelial cells) lining these highways are busy maintaining traffic flow, repairing potholes, and keeping everything running smoothly. They are in a state of growth and repair.

But in Kawasaki Disease (KD), a mysterious condition that strikes young children, this highway suddenly turns into a war zone. The road workers stop fixing potholes and start screaming for help, attracting a massive swarm of angry construction crews (immune cells) that end up tearing the road apart. This leads to dangerous swelling and aneurysms (bulging weak spots) in the heart's arteries.

For years, doctors have struggled to diagnose KD quickly because its symptoms (like a high fever) look just like a common flu or infection. By the time the classic signs appear, the damage might already be done.

This paper tells the story of how scientists finally found the "smoking gun"—a tiny molecule that acts as the switch flipping the road workers from "repair mode" to "war mode"—and discovered a new way to sound the alarm early.

---

1. The Tiny Trigger: miR-10b-5p

Think of miR-10b-5p as a mischievous little puppet master. In healthy children, this puppet master is quiet. But in children with Kawasaki Disease, it wakes up and starts pulling the wrong strings.

The researchers found that this tiny molecule is skyrocketing in the blood of KD patients. To prove it was the culprit, they used two different "test tracks" (mouse models) that mimic the disease. When they injected a "silencer" to stop the puppet master from working, the inflammation in the mice's blood vessels calmed down significantly. It was like taking the puppet master's strings away; the chaos stopped.

2. The Hijacking: Turning Workers into Warriors

So, what does this puppet master actually do?

Inside the blood vessel lining, there are genes that act like instruction manuals for the cells. Two of these manuals are called MKI67 and CBX5.

• MKI67 is the "Growth Manual": It tells cells to multiply and repair.
• CBX5 is the "Chromatin Organizer": It helps keep the cell's DNA tidy and focused on growth.

The puppet master (miR-10b-5p) grabs these manuals and shreds them. Without these instructions, the cells stop growing and repairing. Instead, they undergo a dramatic personality shift. They stop being "road workers" and transform into "angry alarmists."

3. The New Boss: CEBPA and the Siren Song

Once the growth manuals are destroyed, a new boss steps in: a transcription factor called CEBPA.

Think of CEBPA as a hype-man who finds a megaphone. Because the cell is now in a state of confusion (due to the shredded manuals), CEBPA takes over and starts shouting a specific message: "Call the Neutrophils!"

The message is encoded in a chemical signal called CXCL8 (also known as IL-8).

• CXCL8 is like a siren or a beacon.
• When the blood vessel cells start pumping out CXCL8, it acts like a homing beacon for neutrophils (a type of white blood cell).
• The neutrophils swarm to the spot, thinking they are there to help, but they end up causing massive inflammation and damaging the vessel walls.

4. The Breakthrough: A New Early Warning System

Here is the most exciting part for doctors and parents.

Usually, doctors have to wait for a child to show a rash, red eyes, and swollen lymph nodes before they can diagnose Kawasaki Disease. By then, the "siren" (CXCL8) has been blaring for a while, and the damage is underway.

The researchers discovered that CXCL8 levels in the blood are sky-high the moment a child walks into the emergency room with a fever, even before the other symptoms appear.

• The Analogy: Imagine a fire alarm. Usually, we wait until we see smoke (the rash) to know there's a fire. This study found that the siren itself (CXCL8) is loud enough to hear the moment the spark starts, long before the smoke clears.

They tested this in real patients and found that measuring CXCL8 could distinguish Kawasaki Disease from other fevers with high accuracy (about 83% sensitivity and specificity).

5. The Big Picture: A Chain Reaction

The paper connects all the dots in a single chain reaction:

1. The Spark: Something (perhaps a virus or bacteria) triggers the release of miR-10b-5p.
2. The Sabotage: miR-10b-5p destroys the Growth Manuals (MKI67/CBX5).
3. The Takeover: The cell switches to CEBPA mode.
4. The Alarm: CEBPA turns on the CXCL8 siren.
5. The Chaos: Neutrophils swarm, causing vasculitis (blood vessel inflammation).

Why This Matters

• Faster Diagnosis: Doctors might soon be able to use a simple blood test for CXCL8 to catch Kawasaki Disease in its earliest, most treatable stage, preventing heart damage.
• New Treatments: Understanding this chain reaction opens the door for new drugs. Instead of just treating the symptoms, we could potentially design drugs to block the puppet master (miR-10b-5p) or silence the siren (CXCL8), stopping the disease before it starts.

In short, this study found the switch that turns a healthy blood vessel into an inflamed one and gave us a flashlight to see the disease before it becomes dangerous.

Technical Summary

1. Problem Statement

Kawasaki Disease (KD) is an acute systemic vasculitis and the leading cause of acquired heart disease in children, primarily characterized by coronary artery aneurysms. Despite its severity, the etiology remains unclear, and there are no specific biomarkers for early diagnosis in the Emergency Department (ED). Current diagnosis relies on clinical criteria (fever, rash, etc.), which often leads to delayed intervention, increasing the risk of coronary artery damage. Furthermore, a subset of patients is refractory to the standard treatment (Intravenous Immunoglobulin, IVIG). The study aims to elucidate the molecular mechanisms driving KD vasculitis and identify a clinically actionable early diagnostic marker.

2. Methodology

The study employed a multi-omics approach combining clinical data, in vivo murine models, and high-resolution in vitro cellular analyses:

• Clinical Cohort & Sequencing:
  • Samples: Buffy coat and serum were collected from KD patients and febrile controls (non-KD) presenting to the ED.
  • Screening: Whole microRNA (miRNA) sequencing was performed on 5 KD and 5 control samples to identify differentially expressed miRNAs.
  • Validation: Candidate miRNAs were validated in two independent murine KD-like vasculitis models:
    • LCWE Model: Lactobacillus casei cell wall extract injection.
    • CAWS Model: Candida albicans water-soluble fraction injection.
• Functional Validation In Vivo:
  • Loss-of-Function: Locked nucleic acid (LNA) antagomirs targeting miR-10b-5p and miR-125a-3p were administered to LCWE-treated mice to assess their role in aortic root inflammation.
  • Histology: Masson's trichrome staining was used to evaluate aortic valve inflammation and tissue remodeling.
• Mechanistic In Vitro Studies:
  • Cell Models: Human Coronary Artery Endothelial Cells (HCAECs) and Human Coronary Artery Smooth Muscle Cells (HCASMCs) were treated with miR-10b-5p mimics.
  • Single-Cell RNA Sequencing (scRNA-seq): Used to resolve cell-state heterogeneity and transcriptional shifts in HCAECs.
  • Bulk RNA-seq: Performed to capture global transcriptomic shifts and Gene Set Enrichment Analysis (GSEA).
  • ATAC-seq: Assay for Transposase-Accessible Chromatin sequencing to map chromatin accessibility changes.
  • Target Validation: Dual-luciferase reporter assays confirmed direct targeting of MKI67 and CBX5 by miR-10b-5p.
  • Transcription Factor Analysis: Chromatin Immunoprecipitation (ChIP) and in vitro binding assays were used to validate the binding of CEBPA to the CXCL8 and MMP10 promoters.
• Clinical Biomarker Assessment:
  • ELISA: Serum CXCL8 levels were quantified in KD patients vs. controls at initial ED presentation and at an 8-week follow-up.
  • ROC Analysis: Receiver Operating Characteristic curves were generated to evaluate the diagnostic sensitivity and specificity of CXCL8.

3. Key Contributions

The study defines a novel molecular axis driving KD pathogenesis and proposes a new diagnostic strategy:

1. Identification of miR-10b-5p: Established miR-10b-5p as a consistently upregulated and functionally critical driver of KD vasculitis.
2. Mechanism of Endothelial Reprogramming: Demonstrated that miR-10b-5p forces a phenotypic switch in vascular wall cells from a proliferative/metabolic state to a pro-inflammatory state.
3. Elucidation of the Regulatory Axis: Mapped the miR-10b-5p $\rightarrow$ MKI67/CBX5 $\rightarrow$ CEBPA $\rightarrow$ CXCL8/MMP10 pathway.
   • miR-10b-5p directly suppresses MKI67 (proliferation) and CBX5 (chromatin remodeling).
   • This suppression alters chromatin accessibility, facilitating the binding of the transcription factor CEBPA.
   • CEBPA drives the upregulation of CXCL8 (neutrophil chemokine) and MMP10 (matrix metalloproteinase).
4. Diagnostic Biomarker: Validated Serum CXCL8 as a highly sensitive and specific early diagnostic biomarker for KD, detectable before clinical criteria are fully met.

4. Key Results

• miRNA Discovery: 40 miRNAs were upregulated in KD patients. After filtering for stability and abundance, 14 candidates were selected. miR-10b-5p showed the highest fold-change and was consistently elevated in both LCWE and CAWS murine models.
• In Vivo Function: Inhibition of miR-10b-5p using LNA antagomirs significantly attenuated aortic root inflammation in LCWE-treated mice, whereas inhibition of miR-125a-3p had no effect.
• Transcriptomic Reprogramming:
  • scRNA-seq: miR-10b-5p treatment caused a massive shift in HCAEC populations, reducing the proliferative (17% $\rightarrow$ 2%) and metabolic clusters while expanding the inflammatory cluster (3% $\rightarrow$ 65%).
  • Bulk RNA-seq: Confirmed cell-cycle arrest and enrichment of inflammatory pathways (EMT, TNF$\alpha$ signaling) and depletion of cell-cycle pathways.
• Direct Targets & Chromatin Remodeling:
  • Dual-luciferase assays confirmed MKI67 and CBX5 are direct targets of miR-10b-5p.
  • ATAC-seq revealed decreased accessibility at cell-cycle loci (e.g., PCNA, CDK1) and increased accessibility at the promoters of CXCL8 and MMP10.
  • Motif analysis identified CEBPA as the key transcription factor binding to these newly accessible regions. Knockdown of CEBPA abolished the upregulation of CXCL8 and MMP10.
• Clinical Biomarker Performance:
  • Serum CXCL8 was significantly elevated in KD patients at the first ED visit compared to febrile controls.
  • ROC Analysis: CXCL8 achieved 83.33% sensitivity and 83.33% specificity at a cutoff of 20.91 pg/mL.
  • Levels declined significantly by the 8-week follow-up, correlating with clinical resolution.

5. Significance

• Pathophysiological Insight: The study shifts the understanding of KD from a passive inflammatory response to an active endothelial reprogramming event driven by miR-10b-5p. It explains how vascular cells transition from homeostasis to a state that recruits neutrophils and degrades the extracellular matrix (via MMP10), leading to aneurysm formation.
• Clinical Utility: The identification of Serum CXCL8 addresses a critical unmet need for early diagnosis. Unlike current clinical criteria which require the accumulation of symptoms over days, CXCL8 is elevated at the very first presentation, potentially allowing for earlier IVIG administration and reduced coronary artery complications.
• Therapeutic Potential: The defined axis (miR-10b-5p/MKI67/CBX5/CEBPA) offers potential new therapeutic targets. Inhibiting miR-10b-5p or downstream CEBPA activity could theoretically prevent the inflammatory cascade in KD.

In conclusion, this paper provides a comprehensive mechanistic link between circulating miRNAs, chromatin remodeling, and vascular inflammation in Kawasaki Disease, while simultaneously offering a validated biomarker to improve early clinical management.